Neurogene
Robb Sorensen has a strong background in clinical operations and management. Robb is currently working as the Senior Director of Clinical Operations at Neurogene Inc. Prior to this, Robb served as the Senior Director of Clinical Services at Bausch Health Companies Inc. from April 2020 to 2021. Robb also held the position of Director of Clinical Operations at Clinical Network Services (CNS) Pty Ltd from August 2018 to April 2020. Before that, they worked as the Director of Clinical Operations at Achillion Pharmaceuticals, Inc. from January 2014 to August 2018. Robb has also held various roles in clinical project management and operations at Ipsen, Pharmasset, Inc./Gilead Sciences, and Regeneron Pharmaceuticals. Their early experience includes working as a Regional CRA at Schering-Plough Research Institute and as a Senior Clinical Trial Associate at ALTANA Pharma/Nycomed.
Robb Sorensen earned their Bachelor of Science (BS) degree in Business Administration and Management from the University of North Carolina at Charlotte. Robb attended the university from 1994 to 2000.
This person is not in any offices
Neurogene
Neurogene was founded to bring life-changing medicines to patients and families affected by rare neurological disorders. We partner with leading academic researchers, patient advocacy organizations and caregivers to bring to patients therapies that address the underlying genetic cause of a broad spectrum of neurological diseases where no effective treatment options exist today. Our lead programs use AAV-based gene therapy technology to deliver a normal gene to patients with a dysfunctional gene. Neurogene is also investing in novel technology to develop treatments for diseases not well served by gene therapy.